Clinical Trial

Precision Colchicine Intervention to Suppress Atherosclerosis in TET2 Clonal Hematopoiesis

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study aims to investigate whether TET2-associated clonal hematopoiesis of indeterminate potential (TET2-CHIP) can serve as a biomarker to guide precision use of colchicine in a population of clinically stable post-ACS patients receiving standard of care (SoC) therapy. Specifically, we will evaluate whether TET2-CHIP status predicts a differential response to colchicine. As a pilot study, it also aims to provide detailed data supporting design of further trial, such as sample size calculating, endpoint optimizing, etc.
Protocol Amendment History 5 changes
notable Primary completion moved earlier: 2028-05-01 -> 2027-12-01 2026-07-01
minor Completion moved earlier: 2028-08-01 -> 2027-12-01 2026-07-01
critical Recruitment opened 2026-06-19
notable Primary completion pushed: 2027-08-01 -> 2028-05-01 2026-06-19
minor Completion pushed: 2027-08-01 -> 2028-08-01 2026-06-19
Trial Details
NCT Number NCT07362966
Lead Sponsor Shenyang Northern Hospital
Conditions Colchicine, Coronary Atherosclerosis Management, Clonal Hematopoiesis of Indeterminate Potential
Enrollment 120 participants
Start Date 2026-06-08
Primary Completion 2027-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-30